TY - JOUR
T1 - The impact of cancer treatment on quality of life in patients with pancreatic and periampullary cancer
T2 - a propensity score matched analysis
AU - Mackay, Tara M.
AU - Dijksterhuis, Willemieke P. M.
AU - Latenstein, Anouk E. J.
AU - van der Geest, Lydia G.
AU - Sprangers, Mirjam A. G.
AU - van Eijck, Casper H. J.
AU - Homs, Marjolein Y. V.
AU - Luelmo, Saskia A. C.
AU - Molenaar, I. Quintus
AU - van Santvoort, Hjalmar
AU - Dutch Pancreatic Cancer Group
AU - Schreinemakers, Jennifer M. J.
AU - Wilmink, Johanna W.
AU - Besselink, Marc G.
AU - van Laarhoven, Hanneke W.
AU - van Oijen, Martijn G. H.
N1 - Funding Information: This work was supported by the Dutch Cancer Society for the Dutch Pancreatic Cancer Project (grant number UVA2013-5842 ). The funding source played no role. Publisher Copyright: © 2021 The Authors
PY - 2022/4
Y1 - 2022/4
N2 - Background: The impact of pancreatic and periampullary cancer treatment on health-related quality of life (HRQoL) is unclear. Methods: This study merged data from the Netherlands Cancer Registry with EORTC QLQ-C30 and -PAN26 questionnaires at baseline and three-months follow-up of pancreatic and periampullary cancer patients (2015–2018). Propensity score matching (1:3) of group without to group with treatment was performed. Linear mixed model regression analyses were performed to investigate the association between cancer treatment and HRQoL at follow-up. Results: After matching, 247 of 629 available patients remained (68 (27.5%) no treatment, 179 (72.5%) treatment). Treatment consisted of resection (n = 68 (27.5%)), chemotherapy only (n = 111 (44.9%)), or both (n = 40 (16.2%)). At follow-up, cancer treatment was associated with better global health status (Beta-coefficient 4.8, 95% confidence-interval 0.0–9.5) and less constipation (Beta-coefficient −7.6, 95% confidence-interval −13.8–1.4) compared to no cancer treatment. Median overall survival was longer for the cancer treatment group compared to the no treatment group (15.4 vs. 6.2 months, p < 0.001). Conclusion: Patients undergoing treatment for pancreatic and periampullary cancer reported slight improvement in global HRQoL and less constipation at three months-follow up compared to patients without cancer treatment, while overall survival was also improved.
AB - Background: The impact of pancreatic and periampullary cancer treatment on health-related quality of life (HRQoL) is unclear. Methods: This study merged data from the Netherlands Cancer Registry with EORTC QLQ-C30 and -PAN26 questionnaires at baseline and three-months follow-up of pancreatic and periampullary cancer patients (2015–2018). Propensity score matching (1:3) of group without to group with treatment was performed. Linear mixed model regression analyses were performed to investigate the association between cancer treatment and HRQoL at follow-up. Results: After matching, 247 of 629 available patients remained (68 (27.5%) no treatment, 179 (72.5%) treatment). Treatment consisted of resection (n = 68 (27.5%)), chemotherapy only (n = 111 (44.9%)), or both (n = 40 (16.2%)). At follow-up, cancer treatment was associated with better global health status (Beta-coefficient 4.8, 95% confidence-interval 0.0–9.5) and less constipation (Beta-coefficient −7.6, 95% confidence-interval −13.8–1.4) compared to no cancer treatment. Median overall survival was longer for the cancer treatment group compared to the no treatment group (15.4 vs. 6.2 months, p < 0.001). Conclusion: Patients undergoing treatment for pancreatic and periampullary cancer reported slight improvement in global HRQoL and less constipation at three months-follow up compared to patients without cancer treatment, while overall survival was also improved.
UR - http://www.scopus.com/inward/record.url?scp=85116852979&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.hpb.2021.09.003
DO - https://doi.org/10.1016/j.hpb.2021.09.003
M3 - Article
C2 - 34635432
SN - 1365-182X
VL - 24
SP - 443
EP - 451
JO - HPB
JF - HPB
IS - 4
ER -